To The Moon

$Aligos Therapeutics, Inc.(ALGS)$ 

🚀🔬🚀📈🅱️ U͎ L͎ L͎ I͎ S͎ H͎ 🚀🔬🚀

🚀🔬🔥 $ALGS, Biotech Breakout with Institutional Backing and Major Upside! 💡🔬📈

🌟 Picture this: Yesterday, I found myself immersed in the Museum of Old and New Art (MONA) in Tasmania 🇳🇿🦘, captivated by some of the most provocative and unconventional works of art I’ve ever encountered. 🎨🖼️ At the same time, I was actively trading $ALGS, seamlessly merging the frontiers of biotech innovation with the avant-garde essence of contemporary art. 🔬✨

After all, why not balance high finance with high culture? 😎📊

In between soaking up MONA’s eccentric vibes and indulging in ocean-fresh oysters, I opened positions in $ALGS on 13Feb24 at $20.95. The stock has already increased 0.44 % above my entry, and this is just the start! Here’s why I’m super excited about this investment.

🔑 Key Highlights:

• $26.0825 per share pricing, right at market value, undeniable proof of institutional bullishness.

• Cash runway extended into H2 2026, giving Aligos ample time to push forward with its Phase 2 clinical trial for ALG-000184.

• Warrants exercisable until 2032 at $26.02, potentially injecting $52.4 million into the company without immediate dilution.

📈 Why This Financing Structure is Genius:

• Shareholder-Friendly: A strategic mix of voting and non-voting shares ensures capital infusion while maintaining governance stability.

• Pre-Funded Warrants: Offers tax benefits and acts as deferred equity, providing strategic flexibility.

• Institutional Backing: With giants like Jefferies and Piper Sandler at the helm, it’s clear where smart money is betting.

💡 Why I’m MEGA Bullish on $ALGS:

The Phase 2 clinical trial for ALG-000184 targets chronic hepatitis B, a market set to explode to $6.2 billion by 2031. Early positive trial results? This isn’t just exciting, it’s a potential game-changer in biotech!

🔑 Key Technical Levels:

• $22.50 Initial Target, watch this space 📈

• Clearing $22.50? $26 in sight! 🚀

🚀📈 Institutional Confidence Backed by Bullish Momentum and Outstanding Upside Potential 🔬💡

Aligos Therapeutics ($ALGS) is shaping up as a biotech powerhouse, driven by solid fundamentals and growing investor confidence. Let’s unpack the key metrics and what they signal for the future.

🔑 Analyst Ratings and Institutional Sentiment:

🟢 67% Buy and 💪 33% Strong Buy from top analysts highlight a broad consensus for upward momentum.

   •   This bullish sentiment is backed by an average price target of $67.50, representing a staggering 221.43% upside from current levels. The highest target touches $75.00, underscoring the confidence analysts have in Aligos’s clinical progress and strategic positioning.

📊 Technical Insights, Short Interest and Volatility:

   •   Short Interest at 22.17% reflects significant short coverage, but with only 1.54 days to cover, any positive catalyst could trigger a short squeeze scenario.

   •   The short volume has fluctuated recently, indicating increasing market attention and potential for a momentum-driven breakout.

💰 Fundamental Analysis:

Aligos demonstrates mixed profitability metrics, but the company’s cash capability and growth potential remain solid. The recent $105 million private placement financing has significantly strengthened its financial position, extending the cash runway into H2 2026 and providing critical support for the Phase 2 clinical trial of ALG-000184.

💡 Strategic Opportunity, The $6.2 Billion Market

The target market for ALG-000184, chronic hepatitis B, is projected to reach $6.2 billion by 2031. With promising trial results so far, Aligos is well-positioned to capture a significant share of this growing market.

🔑 Key Levels to Watch:

   •   $22.50 Initial Target, technical resistance at this level will be crucial for confirming bullish momentum.

   •   $26.00 and Beyond, a breakthrough here could open the path toward the analyst consensus target of $67.50, driven by sustained buying pressure and positive trial updates.

📢 The Verdict:

$ALGS is a high-potential, growth-oriented biotech play with significant institutional backing. With bullish technicals, improving fundamentals and a massive market opportunity, this stock deserves a spot on your watchlist. The favourable short interest data and strong price targets make it a prime candidate for near-term gains.

🇳🇿🌞🦘🏞️ For now, I’m soaking up Tasmania’s culture, trading by day, and plotting my next big move. But $ALGS? It’s not just on my radar, it’s a beacon🚨. The blend of rock-solid fundamentals with technical breakout potential makes it a must-watch 👀.

📢 Please Like, Repost, and Follow for more sharp setups, stock trends, and actionable insights! 🚀📈 Let’s spot the next big movers together and grow our portfolios! 🍀🍀🍀

Happy trading ahead! Cheers, BC 📈🚀🍀🍀🍀

@Tiger_comments @TigerStars @TigerPicks @TigerWire @Daily_Discussion